Eyes On Divestments, Revised Guidance Ahead Of Takeda's Q1
Executive Summary
As Takeda prepares to report its first full quarter post-Shire next week, eyes will be on further strategic divestments and trends that could lead to a raising of guidance in Q2.
You may also be interested in...
Ninlaro Failure Leaves Little In AL Amyloidosis Pipeline
Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.
Novartis Delighted With Xiidra Deal Despite Eye-Watering Price
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.